Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)

An­a­lysts hound Bio­gen with ques­tions over Aduhelm's $56K price point as news of Alzheimer's OK rip­ples through glob­al mar­kets

It’s been near­ly 24 hours since the FDA hand­ed down its con­tro­ver­sial de­ci­sion to ap­prove Bio­gen’s Aduhelm drug for Alzheimer’s dis­ease, and re­ac­tions from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.